Regencell Bioscience (NASDAQ:RGC) Stock Price Down 6.3% – Time to Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares fell 6.3% during trading on Monday . The stock traded as low as $5.50 and last traded at $5.5070. Approximately 74,501 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 323,320 shares. The stock had previously closed at $5.88.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Regencell Bioscience presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The business’s 50 day moving average is $17.72 and its two-hundred day moving average is $24.52.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Trading of Regencell Bioscience

Several institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP bought a new stake in Regencell Bioscience during the 4th quarter valued at approximately $92,000. Amundi bought a new position in Regencell Bioscience in the 1st quarter worth approximately $219,000. Hudson Bay Capital Management LP purchased a new stake in Regencell Bioscience during the 4th quarter valued at approximately $275,000. Bank of America Corp DE grew its holdings in Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares in the last quarter. Finally, Vident Advisory LLC raised its position in shares of Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares during the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.